These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8901674)

  • 1. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.
    Weir EK; Reeve HL; Huang JM; Michelakis E; Nelson DP; Hampl V; Archer SL
    Circulation; 1996 Nov; 94(9):2216-20. PubMed ID: 8901674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anorectic drugs and pulmonary hypertension from the bedside to the bench.
    Michelakis ED; Weir EK
    Am J Med Sci; 2001 Apr; 321(4):292-9. PubMed ID: 11307870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension.
    Weir EK; Reeve HL; Johnson G; Michelakis ED; Nelson DP; Archer SL
    Chest; 1998 Sep; 114(3 Suppl):200S-204S. PubMed ID: 9741569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term effects of the anorectic agent fenfluramine alone and in combination with aminorex on pulmonary and systemic circulation in the pig.
    Mlczoch J; Weir EK; Reeves JT; Grover RF
    Basic Res Cardiol; 1979; 74(3):313-20. PubMed ID: 475736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells.
    Michelakis ED; Weir EK; Nelson DP; Reeve HL; Tolarova S; Archer SL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1143-9. PubMed ID: 10565835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction.
    Hong Z; Smith AJ; Archer SL; Wu XC; Nelson DP; Peterson D; Johnson G; Weir EK
    Circulation; 2005 Sep; 112(10):1494-9. PubMed ID: 16129789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexfenfluramine increases pulmonary artery smooth muscle intracellular Ca2+, independent of membrane potential.
    Reeve HL; Archer SL; Soper M; Weir EK
    Am J Physiol; 1999 Sep; 277(3):L662-6. PubMed ID: 10484475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminorex, dexfenfluramine, and primary pulmonary hypertension.
    Kramer MS; Lane DA
    J Clin Epidemiol; 1998 Apr; 51(4):361-4. PubMed ID: 9539893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anorectics and pulmonary hypertension].
    Bíbová J; Hampl V
    Cas Lek Cesk; 2000 Feb; 139(3):67-70. PubMed ID: 10838744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.
    Rothman RB; Ayestas MA; Dersch CM; Baumann MH
    Circulation; 1999 Aug; 100(8):869-75. PubMed ID: 10458725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs.
    Naeije R; Maggiorini M; Delcroix M; Leeman M; Mélot C
    Am J Respir Crit Care Med; 1996 Nov; 154(5):1347-50. PubMed ID: 8912746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs.
    Naeije R; Wauthy P; Maggiorini M; Leeman M; Delcroix M
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 1):692-7. PubMed ID: 7881658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance.
    Higenbottam T; Marriott H; Cremona G; Laude E; Bee D
    Chest; 1999 Oct; 116(4):921-30. PubMed ID: 10531154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia.
    Eddahibi S; Raffestin B; Launay JM; Sitbon M; Adnot S
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1111-9. PubMed ID: 9563727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels.
    Belohlávková S; Simák J; Kokesová A; Hnilicková O; Hampl V
    J Appl Physiol (1985); 2001 Aug; 91(2):755-61. PubMed ID: 11457791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine.
    Hong Z; Olschewski A; Reeve HL; Nelson DP; Hong F; Weir EK
    Am J Physiol Lung Cell Mol Physiol; 2004 Mar; 286(3):L531-8. PubMed ID: 14607779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1.
    Barman SA; Isales CM
    Pulm Pharmacol Ther; 1998; 11(2-3):183-7. PubMed ID: 9918753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
    Perchenet L; Hilfiger L; Mizrahi J; Clément-Chomienne O
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1108-19. PubMed ID: 11504808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology.
    Reeve HL; Nelson DP; Archer SL; Weir EK
    Am J Physiol; 1999 Feb; 276(2):L213-9. PubMed ID: 9950882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary hypertension and dexfenfluramine.
    Cacoub P; Dorent R; Nataf P; Houppe JP; Piette JC; Godeau P; Gandjbakhch I
    Eur J Clin Pharmacol; 1995; 48(1):81-3. PubMed ID: 7621854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.